Thursday, July 27, 2006

DOJ looking into BMS deal with Apotex on PLAVIX

Further to an earlier report on IPBiz, the DOJ is looking into the BMS deal with Apotex on PLAVIX.

According to Bloomberg, BMS and Aventis learned July 26 of an investigation by the Justice Department's antitrust division, according to similar statements today. Bristol-Myers and Sanofi agreed to pay generic- drug maker Apotex Inc. an unspecified amount to stay off the market with a generic copy of Plavix until 2011.

Only Pfizer Inc.'s Lipitor cholesterol pill had higher sales than Plavix last year, with $12.2 billion.

Other companies also are vying to sell a generic version of the drug, a $4-a-day pill that prevents the formation of blood clots for patients having a heart attack or undergoing artery- clearing procedures. They include including Dr. Reddy's Laboratories Ltd. of Indian and Israel's Teva Pharmaceutical Industries Ltd., the world's biggest maker of generic drugs. Those cases are pending.


Post a Comment

<< Home